• Deutsch
Login

Open Access

  • Home
  • Search
  • Browse
  • Publish
  • FAQ

Refine

Author

  • Aldefeld, Carl Ludwig Wilhelm (2)
  • Ahn, Fr. (1)
  • Akkuş, Baki (1)
  • Atanasov, Dinko (1)
  • Balabanov, Stefan (1)
  • Batran, Salah-Eddin al- (1)
  • Behnes, Carl Ludwig (1)
  • Beyer, Heinrich F. (1)
  • Blume, Carl Ludwig von (1)
  • Bohnenberger, Hanibal (1)
+ more

Year of publication

  • 2019 (2)
  • 1835 (1)
  • 1838 (1)
  • 1843 (1)
  • 1858 (1)
  • 1859 (1)
  • 2014 (1)
  • 2016 (1)

Document Type

  • Book (5)
  • Article (4)

Language

  • German (4)
  • English (4)
  • Latin (1)

Has Fulltext

  • yes (9)

Is part of the Bibliography

  • no (9)

Keywords

  • Chemorefractory advanced gastric cancer (1)
  • FOLFIRI (1)
  • Heavy ion storage ring (1)
  • Orbital electron capture (1)
  • Single particle decay spectroscopy (1)
  • Sunitinib (1)
  • Two body weak decay (1)
  • Tyrosine kinase inhibitor (1)
  • VEGF (1)

Institute

  • Medizin (2)
  • E-Finance Lab e.V. (1)
  • ELEMENTS (1)
  • Physik (1)

9 search hits

  • 1 to 9
  • 10
  • 20
  • 50
  • 100

Sort by

  • Year
  • Year
  • Title
  • Title
  • Author
  • Author
Die Maaße und Gewichte der deutschen Zoll-Vereins-Staaten und vieler anderer Länder und Handelsplätze in ihren gegenseitigen Verhältnissen (1838)
Aldefeld, Carl Ludwig Wilhelm
Levold's von Northof Chronik der Grafen von der Mark und der Erzbischöfe von Cöln : aus Handschriften verbessert und vervollständigt ... (1859)
de Northof, Levoldus ; Tross, Carl Ludwig Philipp
Die älteren und neuen Maaße und Gewichte der königlich preußischen Rheinprovinz : ein Handbuch für Beamte, Kaufleute und Geschäftsmänner / unter mitwirkung des Herrn Fr. Ahn hrsg. von C. L. W. Aldefeld (1835)
Aldefeld, Carl Ludwig Wilhelm ; Ahn, Fr.
Beiträge zur Lehre vom Mechanismus der Harnsecretion (1843)
Ludwig, Carl
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program (2016)
Möhler, Markus ; Gepfner-Tuma, Irina ; Maderer, Annett ; Thuss-Patience, Peter C. ; Rüssel, Jörn ; Hegewisch-Becker, Susanna ; Wilke, Hansjochen ; Batran, Salah-Eddin al- ; Rafiyan, Mohammad-Reza ; Weißinger, Florian ; Schmoll, Hans-Joachim ; Kullmann, Frank ; Fischer von Weikersthal, Ludwig ; Siveke, Jens Thomas ; Weusmann, Jens ; Kanzler, Stephan ; Schimanski, Carl Christoph ; Otte, Melanie ; Schollenberger, Lukas ; König, Jochem ; Galle, Peter Robert
Background: As a multi-targeted anti-angiogenic receptor tyrosine kinase (RTK) inhibitor sunitinib (SUN) has been established for renal cancer and gastrointestinal stromal tumors. In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but limited tumor response. Methods: This double-blind, placebo-controlled, multicenter, phase II clinical trial was conducted to evaluate the efficacy, safety and tolerability of SUN as an adjunct to second and third-line FOLFIRI (NCT01020630). Patients were randomized to receive 6-week cycles including FOLFIRI plus sodium folinate (Na-FOLFIRI) once every two weeks and SUN or placebo (PL) continuously for four weeks followed by a 2-week rest period. The primary study endpoint was progression-free survival (PFS). Preplanned serum analyses of VEGF-A, VEGF-D, VEGFR2 and SDF-1α were performed retrospectively. Results: Overall, 91 patients were randomized, 45 in each group (one patient withdrew). The main grade ≥3 AEs were neutropenia and leucopenia, observed in 56 %/20 % and 27 %/16 % for FOLFIRI + SUN/FOLFIRI + PL, respectively. Median PFS was similar, 3.5 vs. 3.3 months (hazard ratio (HR) 1.11, 95 % CI 0.70–1.74, P = 0.66) for FOLFIRI + SUN vs. FOLFIRI + PL, respectively. For FOLFIRI + SUN, a trend towards longer median overall survival (OS) compared with placebo was observed (10.4 vs. 8.9 months, HR 0.82, 95 % CI 0.50–1.34, one-sided P = 0.21). In subgroup serum analyses, significant changes in VEGF-A (P = 0.017), VEGFR2 (P = 0.012) and VEGF-D (P < 0.001) serum levels were observed. Conclusions: Although sunitinib combined with FOLFIRI did not improve PFS and response in chemotherapy-resistant gastric cancer, a trend towards better OS was observed. Further biomarker-driven studies with other anti-angiogenic RTK inhibitors are warranted. Trial registration: This study was registered prospectively in the NCT Clinical Trials Registry (ClinicalTrials.gov) under NCT01020630 on November 23, 2009 after approval by the leading ethics committee of the Medical Association of Rhineland-Palatinate, Mainz, in coordination with the participating ethics committees (see Additional file 2) on September 16, 2009.
New test of modulated electron capture decay of hydrogen-like ¹⁴²Pm ions: precision measurement of purely exponential decay (2019)
Öztürk, Fatma Cagla ; Akkuş, Baki ; Atanasov, Dinko ; Beyer, Heinrich F. ; Bosch, Fritz ; Boutin, David ; Brandau, Carsten ; Bühler, Paul ; Çakirli Mutlu, Rabia Burcu ; Chen, Ruijiu ; Chen, Weidong ; Chen, Xiangcheng ; Dillmann, Iris ; Dimopoulou, Christina ; Enders, Wolfgang ; Essel, Hans G. ; Faestermann, Thomas ; Forstner, Oliver ; Gao, Bing-Shui ; Geissel, Hans ; Gernhäuser, Roman ; Grisenti, Robert Evaristo ; Gumberidze, Alexandre ; Hagmann, Siegbert ; Heftrich, Tanja ; Heil, Michael ; Herdrich, Marc Oliver ; Hillenbrand, Pierre-Michel ; Izumikawa, Takuji ; Kienle, Paul ; Klaushofer, Christoph ; Kleffner, Carl-Michael ; Kozhuharov, Christophor ; Knöbel, Ronja ; Kovalenko, Oleksandr ; Kreim, Susanne ; Kühl, Thomas ; Lederer-Woods, Claudia ; Lestinsky, Michael ; Litvinov, Sergey A. ; Litvinov, Yuri A. ; Liu, Zhong ; Ma, Xinwen ; Maier, Ludwig W. ; Mei, Bo ; Miura, Hiroshi ; Mukha, Ivan ; Najafi, Mohammad Ali ; Nagae, Daisuke ; Nishimura, Takuro ; Nociforo, Chiara ; Nolden, Fritz ; Ohtsubo, Takashi ; Öktem, Yeşim ; Omika, Shunichiro ; Ozawa, Akira ; Petridis, Nikolaos ; Piotrowski, Jeremi ; Reifarth, René ; Roßbach, Jörg ; Sánchez Alarcón, Rodolfo Marcelo ; Sanjari, Mohammad Shahab ; Scheidenberger, Christoph ; Sidhu, Ragandeep Singh ; Simon, Haik ; Spillmann, Uwe ; Steck, Markus ; Stöhlker, Thomas ; Sun, Baohua ; Susam, Lidya Amon ; Suzaki, Fumi ; Suzuki, Takeshi ; Torilov, Sergey Yu. ; Trageser, Christian ; Trassinelli, Martino ; Trotsenko, Sergiy ; Tu, Xiaolin ; Walker, Philip M. ; Wang, M. ; Weber, Günter ; Weick, Helmut ; Winckler, Nicolas ; Winters, Danyal Ferdinant Alexander ; Woods, Philip John ; Yamaguchi, Takayuki ; Xu, X.D. ; Yan, X.L. ; Yang, Jiancheng ; Yuan, You-Jin ; Zhang, Yuhu ; Zhou, Xiaohong
An experiment addressing electron capture (EC) decay of hydrogen-like 142Pm60+ions has been conducted at the experimental storage ring (ESR) at GSI. The decay appears to be purely exponential and no modulations were observed. Decay times for about 9000 individual EC decays have been measured by applying the single-ion decay spectroscopy method. Both visually and automatically analysed data can be described by a single exponential decay with decay constants of 0.0126(7)s−1 for automatic analysis and 0.0141(7)s−1 for manual analysis. If a modulation superimposed on the exponential decay curve is assumed, the best fit gives a modulation amplitude of merely 0.019(15), which is compatible with zero and by 4.9 standard deviations smaller than in the original observation which had an amplitude of 0.23(4).
Collection des orchidées les plus remarquables de l'Archipel Indien et du Japon (1858)
Blume, Carl Ludwig von
Proteomic comparison of malignant human germ cell tumor cell lines (2019)
Bremmer, Felix ; Bohnenberger, Hanibal ; Küffer, Stefan ; Oellerich, Thomas ; Serve, Hubert ; Urlaub, Henning ; Strauß, Arne ; Maatoug, Yasmine ; Behnes, Carl Ludwig ; Oing, Christoph ; Radzun, Heinz-Joachim ; Ströbel, Philipp ; Balabanov, Stefan ; Honecker, Friedemann
Malignant germ cell tumors (GCT) are the most common malignant tumors in young men between 18 and 40 years. The correct identification of histological subtypes, in difficult cases supported by immunohistochemistry, is essential for therapeutic management. Furthermore, biomarkers may help to understand pathophysiological processes in these tumor types. Two GCT cell lines, TCam-2 with seminoma-like characteristics, and NTERA-2, an embryonal carcinoma-like cell line, were compared by a quantitative proteomic approach using high-resolution mass spectrometry (MS) in combination with stable isotope labelling by amino acid in cell culture (SILAC). We were able to identify 4856 proteins and quantify the expression of 3936. 347 were significantly differentially expressed between the two cell lines. For further validation, CD81, CBX-3, PHF6, and ENSA were analyzed by western blot analysis. The results confirmed the MS results. Immunohistochemical analysis on 59 formalin-fixed and paraffin-embedded (FFPE) normal and GCT tissue samples (normal testis, GCNIS, seminomas, and embryonal carcinomas) of these proteins demonstrated the ability to distinguish different GCT subtypes, especially seminomas and embryonal carcinomas. In addition, siRNA-mediated knockdown of these proteins resulted in an antiproliferative effect in TCam-2, NTERA-2, and an additional embryonal carcinoma-like cell line, NCCIT. In summary, this study represents a proteomic resource for the discrimination of malignant germ cell tumor subtypes and the observed antiproliferative effect after knockdown of selected proteins paves the way for the identification of new potential drug targets.
Market participants should proceed resolutely with SEPA migration (2014)
Thiele, Carl-Ludwig
  • 1 to 9

OPUS4 Logo

  • Contact
  • Imprint
  • Sitelinks